Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study-Reference-Cited by-同舟云学术

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Published:2023-05 Issue:5 Volume:8 Page:446-457
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Tye-Din Jason A^ORCID,Daveson A James M^ORCID,Goel Gautam^ORCID,Goldstein Kaela E^ORCID,Hand Holly L^ORCID,Neff Kristin M^ORCID,Popp Alina^ORCID,Taavela Juha^ORCID,Maki Markku^ORCID,Isola Jorma^ORCID,Williams Leslie J^ORCID,Truitt Kenneth E^ORCID,Anderson Robert P^ORCID,Adams Atoya,Andrews Jane M,Behrend Clint E,Brown Gregor J E,Chen Yi Mei Swee Lin,Coates Allan G,DiMarino Anthony J,Ee Hooi,Elliott David E,Epstein Roger M,Feyen Bryan John,Fogel Ronald P,Friedenberg Keith Alan,Gearry Richard B,Gerdis Michael S,Goldstein Michael J,Gupta Vipin K,Holmes Robert John,Holtmann Gerald J,Idarraga Samuel H,James George W,King Tim,Klein Terry D,Kupfer Sonia S,Lebwohl Benjamin,Lowe Matthew John,Murray Joseph A,Newton Eric B,Quinn Dean,Radin David M,Ritter Timothy E,Stacey Helen Lee,Strout Cynthia B,Stubbs Richard S,Thackwray Susan Lynn,Trivedi Vivek M,Weber John R,Wilson Scott A

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis;Anderson;Expert Rev Clin Immunol,2022

2. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial;Leffler;Gastroenterology,2015

3. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease;Murray;Gastroenterology,2017

4. A randomized trial of a transglutaminase 2 inhibitor for celiac disease;Schuppan;N Engl J Med,2021

5. FDA draft guidance for developing drugs for adjunctive treatment to a gluten-free diet: comments by the society for the study of celiac disease;Gastroenterology,2022

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laboratory Testing for Celiac Disease: Clinical and Methodological Considerations;Clinical Chemistry;2024-08-05

2. Contemporary Perspectives on the Role of Vitamin D in Enhancing Gut Health and Its Implications for Preventing and Managing Intestinal Diseases;Nutrients;2024-07-20

3. Evolution in coeliac disease diagnosis and management;JGH Open;2024-07

4. Celiac disease and nonceliac enteropathies;Current Opinion in Gastroenterology;2024-06-17

5. Celiac disease: Hope for new treatments beyond a gluten-free diet;Clinical Nutrition;2024-06